Bolt Biotherapeutics (BOLT) Accumulated Depreciation (2020 - 2026)

Bolt Biotherapeutics has reported Accumulated Depreciation for 7 years, with the latest figure at $7.5 million in Q1 2026.

• Quarterly Accumulated Depreciation rose 15.98% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.5 million (up 15.98% YoY) and the FY2025 annual result came in at $7.4 million, up 1.5% from the prior year.
• Accumulated Depreciation advanced to $7.5 million in Q1 2026 per BOLT's latest filing, from $7.4 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $7.5 million in Q1 2026 and troughed at $2.6 million in Q1 2022.
• A 5-year average of $5.6 million and a median of $6.2 million in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2022 and 2025: Accumulated Depreciation soared 74.39% in 2022, then increased 1.5% in 2025.
• Over 5 years, Accumulated Depreciation stood at $3.9 million in 2022, then soared by 46.92% to $5.8 million in 2023, then rose by 26.53% to $7.3 million in 2024, then advanced by 1.5% to $7.4 million in 2025, then increased by 1.98% to $7.5 million in 2026.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $7.5 million, $7.4 million, and $7.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.